Torrent Pharmaceuticals Ltd (TORNTPHARM) Price & Analysis

Compare

3 Followers

TORNTPHARM Stock Chart & Stats

₹3578.85

-₹79.35(-2.33%)

At close: Jan 08 4:00 PM EST

₹3578.85

-₹79.35(-2.33%)

Day’s Range― - ―

52-Week Range₹3,031.20 - ₹4,470.00

Previous CloseN/A

Volume167.59K

Average Volume (3M)7.49K

Market Cap

₹1.50T

Enterprise Value₹1.52T

Total Cash (Recent Filing)₹6.88B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)51.3

Beta0.60

Next Earnings

May 21, 2026

EPS Estimate

20.22

Next Dividend Ex-DateN/A

Dividend Yield0.84%

Share Statistics

EPS (TTM)19.00

Shares Outstanding338,431,850

10 Day Avg. Volume2,743

30 Day Avg. Volume7,494

Financial Highlights & Ratios

PEG Ratio3.66

Price to Book (P/B)14.19

Price to Sales (P/S)9.36

P/FCF Ratio54.58

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)71.11

Revenue Forecast (FY)₹134.05B

Bulls Say, Bears Say

Bulls Say

Strong Cash GenerationSustained free cash flow growth (42.48%) and an OCF-to-net-income ratio of 1.35 indicate durable cash conversion. This enhances funding for R&D, capacity expansion, debt reduction, and shareholder returns without relying on external financing, strengthening long-term financial resilience.

Healthy Balance Sheet And Reduced LeverageA ~50.6% equity ratio and lower debt-to-equity (0.42) show improved leverage and financial flexibility. Combined with a strong ROE (~25%), this supports sustainable investment, M&A optionality and weathering regulatory or pricing shocks without materially increasing refinancing risk over the medium term.

Robust Margins With Steady Revenue GrowthHigh gross and EBIT margins with consistent revenue growth reflect structural pricing power, efficient manufacturing and operating leverage in core therapies. These margin levels provide room to fund commercialization and geographic expansion while protecting profitability across market cycles.

Bears Say

Net Profit Margin Compression RiskA materially lower net margin versus gross/EBIT margins suggests downstream cost, tax or financing pressures that erode final earnings. If structural SG&A, pricing pressure, or tax impacts persist, they could limit retained earnings and slower reinvestment or dividend growth over the medium term.

Need To Improve Asset UtilizationSuboptimal asset utilization can constrain revenue per invested asset and depress returns on capital over time. Sustained underuse of manufacturing or distribution capacity would require either incremental capital or efficiency gains to maintain growth and the high ROE observed today.

Exposure To Pricing, Tender And Regulatory DynamicsDependence on branded generics and international tender/pricing mechanisms creates structural revenue volatility. Regulatory approvals and manufacturing-site clearances are binary events that can materially affect supply and market access, posing medium-term execution and margin risk unless diversified further.

Torrent Pharmaceuticals Ltd News

Torrent Pharma Plans Global Investor Meetings in March 2026

Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) just unveiled an update. Torrent Pharmaceuticals Limited has announced a series of...

16d ago

Torrent Pharma to Shift Registered Office Within Ahmedabad

The latest announcement is out from Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ). Torrent Pharmaceuticals Limited has approved the...

1M ago

Torrent Pharma Raises ₹11,000 Crore via Multi-series Listed NCD Issue

Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) has provided an update. Torrent Pharmaceuticals Ltd has raised long-term debt capital...

2M ago

Torrent Pharma Clears ₹12,500-Crore Secured NCD Issue on Private Placement

Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) has shared an announcement. Torrent Pharmaceuticals Ltd has approved the issuance of...

2M ago

Torrent Pharma to Raise Up to ₹12,500 Crore via Secured NCDs on Private Placement Basis

An announcement from Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) is now available. Torrent Pharmaceuticals Limited has approved the...

2M ago

India Ratings Affirms Torrent Pharma at IND AA+(Stable), Assigns IND A1+ to Commercial Paper

Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) just unveiled an announcement. Torrent Pharmaceuticals Limited announced that India Ratings and...

2M ago

Torrent Pharmaceuticals Opens Special Window for Physical Share Transfers

The latest announcement is out from Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ). Torrent Pharmaceuticals Ltd has announced a...

3M ago

Torrent Pharmaceuticals Faces GST Penalty, Plans to Appeal

Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) has shared an update. Torrent Pharmaceuticals Ltd has disclosed that the Joint...

3M ago

Torrent Pharma Secures CCI Approval for J.B. Chemicals Acquisition

An update from Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) is now available. Torrent Pharmaceuticals Ltd has received approval...

5M ago

Torrent Pharmaceuticals Releases Q1 2025 Financial Results Conference Call Recording

An announcement from Torrent Pharmaceuticals Ltd ( ($IN:TORNTPHARM) ) is now available. Torrent Pharmaceuticals Ltd has announced the...

8M ago

TORNTPHARM FAQ

What was Torrent Pharmaceuticals Ltd’s price range in the past 12 months?

Torrent Pharmaceuticals Ltd lowest stock price was ₹3031.20 and its highest was ₹4470.00 in the past 12 months.

What is Torrent Pharmaceuticals Ltd’s market cap?

Torrent Pharmaceuticals Ltd’s market cap is ₹1.50T.

When is Torrent Pharmaceuticals Ltd’s upcoming earnings report date?

Torrent Pharmaceuticals Ltd’s upcoming earnings report date is May 21, 2026 which is in 69 days.

How were Torrent Pharmaceuticals Ltd’s earnings last quarter?

Torrent Pharmaceuticals Ltd released its earnings results on Feb 13, 2026. The company reported ₹19 earnings per share for the quarter, beating the consensus estimate of ₹18.196 by ₹0.804.

Is Torrent Pharmaceuticals Ltd overvalued?

According to Wall Street analysts Torrent Pharmaceuticals Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Torrent Pharmaceuticals Ltd pay dividends?

Torrent Pharmaceuticals Ltd pays a Notavailable dividend of ₹6 which represents an annual dividend yield of 0.84%. See more information on Torrent Pharmaceuticals Ltd dividends here

What is Torrent Pharmaceuticals Ltd’s EPS estimate?

Torrent Pharmaceuticals Ltd’s EPS estimate is 20.22.

How many shares outstanding does Torrent Pharmaceuticals Ltd have?

Torrent Pharmaceuticals Ltd has 338,431,850 shares outstanding.

What happened to Torrent Pharmaceuticals Ltd’s price movement after its last earnings report?

Torrent Pharmaceuticals Ltd reported an EPS of ₹19 in its last earnings report, beating expectations of ₹18.196. Following the earnings report the stock price went down -0.185%.

Which hedge fund is a major shareholder of Torrent Pharmaceuticals Ltd?

Currently, no hedge funds are holding shares in IN:TORNTPHARM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.